3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
1
Status
Completed
3
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Breast
3
Gastrointestinal
2
Genitourinary
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
308
Lung Neoplasms
70
Neoplasms
50
Neoplasm Metastasis
33
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Colorectal Neoplasms
20
Carcinoma
20
Mesothelioma
15
Breast Neoplasms
15
Mesothelioma, Malignant
13
Small Cell Lung Carcinoma
11
Melanoma
10
Adenocarcinoma
10
Neoplasms by Site
9
Adenocarcinoma of Lung
8
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Lung Diseases
7
Thoracic Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Non-Squamous Non-Small Cell Lung Cancer
6
Uterine Cervical Neoplasms
5
Respiratory Tract Neoplasms
5
Respiratory Tract Diseases
5
Recurrence
5
Rectal Neoplasms
5
Neoplasms by Histologic Type
5
NSCLC
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
Pemetrexed
×
Clear all
NCT03396445
2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1
Completed
182 enrolled
36 charts
NCT03267316
2024-08-22
CANFOUR
Cantargia AB
Phase 1/2
Completed
167 enrolled
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts